Close Menu

Huntington's disease

NEW YORK (GenomeWeb News) – Proteome Sciences said today that it will collaborate with CHDI Foundation on research into protein biomarkers for Huntington's disease.

NEW YORK (GenomeWeb News) – GNS Healthcare and the CHDI Foundation jointly announced today that they will collaborate on the development of a data-driven computer model of Huntington's disease intended to drive personalized medicine research.

NEW YORK (GenomeWeb News) – Thomson Reuters' Intellectual Property & Science business announced a deal with the CHDI Foundation to develop systems biology tools for Huntington's disease.

NEW YORK (GenomeWeb News) – KineMed and CHDI Foundation announced late on Monday a partnership to use KineMed's technology to investigate the turnover rates of huntingtin protein, which plays a crucial role in the pathogenesis of Huntington's disease.

Alnylam Pharmaceuticals executives last week disclosed that the company has dropped out of its 50/50 cost- and profit-sharing arrangement with Medtronic for the preclinical RNAi-based Huntington's disease therapy ALN-HTT, opting instead to let its partner incur all expenses assoc

One award will be used to create methods of identifying potentially cancer-causing or other detrimental mutations in induced pluripotent stem cells, and the other will be used to conduct research into a group of genetic diseases.

The firm will provide the foundation with structure-based drug discovery services.

Although Lundbeck's foray into the RNAi drugs scene is modest compared with investments made by other pharmas, it comes at a time when many of those firms have put the brakes on their commitment to the approach.

Pages

A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.

According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.